SK 216 |
| カタログ番号GC50372 |
プラスミノーゲン活性化因子阻害剤-1（PAI-1）阻害剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 654080-03-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Plasminogen activator inhibitor-1 (PAI-1) inhibitor. Inhibits VEGF-induced migration and tube formation in HUVECs. Also attenuates TGF-β dependent epithelial-mesenchymal transition and fibroblast to myofibroblast differentiation in vitro. Reduces size and weight of subcutaneous tumors, and inhibits metastasis and angiogenesis in vivo. Reduces bleomycin-induced pulmonary fibrosis in vivo. Orally bioavailable.
Omori et al (2016) Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS One. 11 e0148969 PMID:26859294 |Takayama et al (2016) Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma. Cancer Res. 76 3285 PMID:27197170 |Masuda et al (2013) SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol.Cancer Ther. 12 2378 PMID:23990114
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *